Skip to main content
  • Offering
    • Offering
    • Integrated Biologics
      • Integrated Biologics
      • Expression Technologies
        • Expression Technologies
        • GS Xceed® Gene Expression System
        • GS piggyBac® Transposon Technology
        • GS Effex® Cell Line
        • GS Discovery® Transient Expression
        • bYlok® Bispecific Pairing Technology
        • XS Technologies® Platform
        • Technical Support
      • Early Derisking and Optimization
        • Early Derisking and Optimization
        • Developability Assessment
        • Manufacturability Assessment
        • Biologics Formulatability
        • Immunogenicity / Immunotoxicity Assessment
        • ​​Early Protein Expression​​​ Services​​
      • Integrated DNA-to-IND Programs
        • Integrated DNA-to-IND Programs
        • mAbs DNA-to-IND Program
        • Bispecifics DNA-to-IND Program
        • Fabs and Fc-Fusion Proteins DNA-to-IND Programs
        • Scaffolds and other Recombinant Proteins
      • Development Services
        • Development Services
        • Biologics Process Development
        • Biologics Analytical Development
        • Formulation and Primary Packaging Development
      • Manufacturing
        • Manufacturing
        • Mammalian Drug Substance Manufacturing
        • Drug Product Manufacture
        • OptiALTO™ Intensified Fed-Batch Platform
      • Mammalian Biopharmaceutical Services
        • Mammalian Biopharmaceutical Services
        • Cell Line Development
        • Tailored License Application Program
        • Process Development
      • Drug Product Services
      • Biologics Regulatory Affairs Services
      • Knowledge Center
    • Advanced Synthesis
      • Advanced Synthesis
      • Small Molecules
        • Small Molecules
        • Drug Substance/API Services
          • Drug Substance/API Services
          • Accelerate Early Drug Development with Lonza Design2Optimize®
          • Early Phase Small Molecule Development Services
          • API Support for Early Phase Development
          • AI-Enabled Route Scouting Service
          • Solid Form Drug Services
          • PBPK Modeling Services
          • High-Throughput Experimentation (HTE) | Accelerate Chemical Optimization with Lonza
          • Pharmaceutical Method Development
          • Commercial API Manufacturing Services
          • Highly Potent API Technologies
            • Highly Potent API Technologies
            • HPAPI Handling and Development
            • HPAPI Manufacturing | Low & High Potency
          • ADC Clinical and Commercial Manufacturing
          • ADC Payload Product Development
        • Particle Engineering
          • Particle Engineering
          • Solid Dispersion Technology
          • Bioavailability Enhancement
          • Spray-Dried Dispersion Technology
        • Drug Product
          • Drug Product
          • Clinical Trial Material Manufacture, Supply
          • Formulation and Development
          • Design and Preformulation Development
          • Drug Development Workflow & Pharmaceutical Process Optimization
          • Inhalation Formulation Development
          • Integrated Offerings
        • Regulatory Affairs CMC Services
          • Regulatory Affairs CMC Services
          • CMC Development Services | CMC Regulatory Submissions
      • Bioconjugation Services
        • Bioconjugation Services
        • Early Development Bioconjugate Services | ADCs
        • ADC Drug Substance Manufacturing
        • Pharmaceutical, ADC Analytical Services
        • Targeting Agent and Carrier Protein
        • ADC Process Development
        • Ibex® Design ADC, DNA-to-IND Program
      • ADC Technologies Platform
      • Knowledge Center
    • Specialized Modalities
      • Specialized Modalities
      • Cell & Gene
        • Cell & Gene
        • Process Development
        • cGMP Manufacturing
        • Allogeneic
        • Autologous
        • Viral Vectors
        • Exosomes
      • Microbial
        • Microbial
        • Microbial Strain Development
        • Process Development
        • Drug Substance Manufacturing
        • Analytical Development
      • mRNA/LNP
        • mRNA/LNP
        • Process Development
        • Analytical Services
        • mRNA Manufacturing
        • Lipid Nanoparticles Encapsulation
      • Bioscience Products
      • Knowledge Center
    • Knowledge Center
  • Company
    • Company
    • About Us
      • About Us
      • Our One Lonza Strategy
      • Our Leadership
        • Our Leadership
        • Executive Committee
        • Board of Directors
        • Board Committees
      • Our History
      • Our Locations
    • News and Media
      • News and Media
      • News Releases
      • Images and Videos
      • Logo Guidelines
      • Blog
      • A View On - Lonza Podcast
      • Journalist Inquiries
    • Investor Relations
      • Investor Relations
      • Shareholder and Bondholder Information
        • Shareholder and Bondholder Information
        • Consensus and Analysts
        • Bond Investors and Credit Information
        • Investor FAQ
        • Share Buyback
      • Agenda and Events
      • Reporting and Presentations
      • Corporate Governance
      • Ethics and Compliance
      • Investor Inquiries and Feedback
    • Sustainability
      • Sustainability
      • Environment
      • People and Society
      • Compliance and Integrity
      • Responsible Sourcing
      • Global Quality
  • Careers
    • Careers
    • Welcome to Lonza
    • Life at Lonza
    • Employee Benefits
    • Early Career Opportunities
    • Inclusion, Diversity and Belonging
    • Join Our Talent Community
  • Contact Search
  • Cancel
DJI_0007

  • Home
  • Visp, Switzerland
  • Gamsenried
  • Alte Deponie Gamsenried
  • Weitere Informationen
  • Geschichte
    1918-1970 1941-1970 1960-1978 1978-2011 Die alte Deponie aktuell
  • Belastungen
    Quecksilber Benzidin Weitere Substanzen Studien
  • Sanierungsprozess
    Prozessablauf Aktueller Stand des Sanierungsprozesses Massnahmen Finanzierung
  • Weitere Informationen
    Glossar Medienmitteilungen Links

Glossar

  • AltlV: Altlastenverordnung
  • Nanogramm: ein Nanogramm ist ein Milliardstel eines Gramms
  • TVA: Technische Verordnung über Abfälle
  • VVEA: Verordnung über die Vermeidung und die Entsorgung von Abfällen

Medienmitteilungen

26. Januar 2022
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)

23. Juli 2021
Lonza meldet starke Dynamik in H1 2021 mit 14.7% Umsatzwachstum (kWk) und 33.3% Kern-EBITDA Marge

14. April 2021
Alte Deponie Gamsenried: Start der Arbeiten zur Erweiterung der Biosparging-Anlage in Brigerbad

15. September 2020
Alte Deponie Gamsenried: Lonza zeigt mögliche Sanierungsvarianten auf

7. April 2020
Lonza treibt Umsetzung von Massnahmen zur Verringerung der Benzidin-Belastungen voran

18. Oktober 2019
Lonza untersucht Bewässerungsbrunnen – zwei private Brunnen mit Benzidin belastet

1. April 2019
Schadstoff-Belastung des Grundwassers im Abstrom der alten Deponie Gamsenried

5. September 2018
Lonza investiert in die Zukunft. Das bedeutet auch die Aufarbeitung der Vergangenheit.

25. Februar 2016
Weiteres Vorgehen bei den Untersuchungen auf der alten Deponie Gamsenried


Links

Kanton Wallis (Deponiewebseite)
Dienststelle für Umwelt Kanton Wallis, DUW
Bundesamt für Umwelt, BAFU
Grosse Altlastensanierungen: Acht Porträts
Gemeinde Brig-Glis
Gemeinde Visp
Altlastenverordnung
Verordnung über die Vermeidung und die Entsorgung von Abfällen (VVEA)
Who we are
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
Quick Links
  • Reporting Center
  • Upcoming Events
  • Knowledge Center
  • Meet The Experts
  • Our Locations
  • California CCPA Notice
  • Transparency in Coverage
Get in touch
  • Contact Us
  • Regulatory Support
© 2026 Lonza. All rights reserved.
Cookie Settings | Terms and Conditions | Legal Disclaimer | Privacy Policy | Accessibility | Sitemap